Ingrid Teige

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 30, 2026

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

Journal: Cancer research

Published: January 16, 2026

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Journal: Immunity

Published: July 02, 2025

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 15, 2025

A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

Journal: Cancer immunology research

Published: November 04, 2024

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

Journal: Cell reports

Published: February 20, 2022

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.

Journal: Journal for immunotherapy of cancer

Published: December 27, 2021

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Journal: Journal of hematology & oncology

Published: December 23, 2021

Domain binding and isotype dictate the activity of anti-human OX40 antibodies.

Domain binding and isotype dictate the activity of anti-human OX40 antibodies.

Journal: Journal for immunotherapy of cancer

Published: November 24, 2020

FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

Journal: Frontiers in immunology

Published: October 06, 2020

Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.

Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.

Journal: Nature communications

Published: October 02, 2020

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.

Journal: Frontiers in immunology

Published: November 30, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026